Correlation Between GlaxoSmithKline PLC and ProShares Trust

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both GlaxoSmithKline PLC and ProShares Trust at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GlaxoSmithKline PLC and ProShares Trust into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between GlaxoSmithKline PLC ADR and ProShares Trust, you can compare the effects of market volatilities on GlaxoSmithKline PLC and ProShares Trust and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GlaxoSmithKline PLC with a short position of ProShares Trust. Check out your portfolio center. Please also check ongoing floating volatility patterns of GlaxoSmithKline PLC and ProShares Trust.

Diversification Opportunities for GlaxoSmithKline PLC and ProShares Trust

-0.69
  Correlation Coefficient

Excellent diversification

The 3 months correlation between GlaxoSmithKline and ProShares is -0.69. Overlapping area represents the amount of risk that can be diversified away by holding GlaxoSmithKline PLC ADR and ProShares Trust in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ProShares Trust and GlaxoSmithKline PLC is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GlaxoSmithKline PLC ADR are associated (or correlated) with ProShares Trust. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ProShares Trust has no effect on the direction of GlaxoSmithKline PLC i.e., GlaxoSmithKline PLC and ProShares Trust go up and down completely randomly.

Pair Corralation between GlaxoSmithKline PLC and ProShares Trust

Considering the 90-day investment horizon GlaxoSmithKline PLC ADR is expected to under-perform the ProShares Trust. But the stock apears to be less risky and, when comparing its historical volatility, GlaxoSmithKline PLC ADR is 5.77 times less risky than ProShares Trust. The stock trades about -0.23 of its potential returns per unit of risk. The ProShares Trust is currently generating about 0.2 of returns per unit of risk over similar time horizon. If you would invest  1,489  in ProShares Trust on August 30, 2024 and sell it today you would earn a total of  1,294  from holding ProShares Trust or generate 86.9% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

GlaxoSmithKline PLC ADR  vs.  ProShares Trust

 Performance 
       Timeline  
GlaxoSmithKline PLC ADR 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days GlaxoSmithKline PLC ADR has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
ProShares Trust 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in ProShares Trust are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent technical indicators, ProShares Trust unveiled solid returns over the last few months and may actually be approaching a breakup point.

GlaxoSmithKline PLC and ProShares Trust Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with GlaxoSmithKline PLC and ProShares Trust

The main advantage of trading using opposite GlaxoSmithKline PLC and ProShares Trust positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GlaxoSmithKline PLC position performs unexpectedly, ProShares Trust can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProShares Trust will offset losses from the drop in ProShares Trust's long position.
The idea behind GlaxoSmithKline PLC ADR and ProShares Trust pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Other Complementary Tools

Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bonds Directory
Find actively traded corporate debentures issued by US companies